Shares of Edgewise Therapeutics, Inc. (EWTX) surged 5.33% in the pre-market session on Friday, as analysts expressed optimism about the healthcare company's prospects.
Scotiabank initiated coverage on EWTX with an Outperform rating and a $50 price target, citing expectations of positive momentum for the company. The firm believes that Edgewise Therapeutics' pipeline and potential in the healthcare sector could drive significant growth in the future.
The positive analyst sentiment has boosted investor confidence in EWTX, leading to the stock's pre-market rally. As more analysts weigh in on the company, the market's outlook on Edgewise Therapeutics may continue to improve, potentially supporting further upward movement in the stock price.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。